Boston Scientific prices $3 billion and €4.25 billion of notes to fund Penumbra deal

Editorial illustration: Cream and blue certificates curve into a gold connector joining navy and teal display cases containing medical devices and flexible tubing.

In brief

  • Boston Scientific priced $3 billion of US dollar notes across four tranches, per its Nov. 19 release.
  • A Boston Scientific finance subsidiary priced €4.25 billion of euro notes across six tranches.
  • Proceeds are earmarked for the cash consideration in the Penumbra, Inc. acquisition.
  • Most series carry a 101% special mandatory redemption if the Penumbra deal isn't completed.

Ten tranches, two currencies

The dollar side is split four ways. Per the company's Nov. 19 release, it includes $1 billion of 5.375% Senior Notes due 2029 and $750 million of 5.500% Senior Notes due 2031, plus $750 million of 5.750% notes due 2033 and $500 million of 5.875% notes due 2036. BofA Securities, Citigroup Global Markets and J.P. Morgan Securities were joint book-running managers on the USD offering.

The euro notes came through a different entity. American Medical Systems Europe B.V. (an indirect wholly owned finance subsidiary of Boston Scientific) priced six tranches: €500 million of Floating Rate Notes due 2028, €500 million of 3.875% notes due 2028, €750 million of 4.125% notes due 2030, €750 million of 4.500% notes due 2034, €1 billion of 4.750% notes due 2038 and €750 million of 5.125% notes due 2046.

That's ten tranches in total, stretching out to 2046.

What the money's for

Proceeds are going toward the cash consideration in the Penumbra deal. Boston Scientific said it'll combine them with short-term borrowings and/or borrowings under its credit agreement(s), along with cash on hand. December 1, 2026 is the company's stated closing date, not a completed outcome.

The notes come with a fallback. Every series except the Floating Rate Notes is subject to a special mandatory redemption at 101% of principal, plus accrued and unpaid interest, if the acquisition isn't completed by the applicable end date. The same redemption applies if the issuer notifies the trustee that the company won't pursue the deal.

The company behind the deal

Boston Scientific describes itself as a global medical technology leader for more than 45 years. It's based in Marlborough, Mass., and it's listed on the NYSE under BSX. Its devices and therapies, the company said, help physicians diagnose and treat cardiovascular, respiratory, digestive, oncological, neurological and urological conditions.

Frequently asked questions

How is Boston Scientific paying for the Penumbra acquisition?

Boston Scientific earmarked proceeds from its $3 billion and €4.25 billion note offerings for the cash consideration in the Penumbra, Inc. acquisition. The company said it will combine those proceeds with short-term borrowings and/or borrowings under its credit agreement(s) and cash on hand.

What happens to the notes if the Penumbra deal doesn't close?

Every series except the Floating Rate Notes is subject to a special mandatory redemption at 101% of principal plus accrued and unpaid interest if the acquisition isn't completed by the applicable end date. The same redemption applies if the issuer notifies the trustee that the company won't pursue the deal.